Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ).
IRLAB Therapeutics AB announced that the European Patent Office intends to grant a new patent for mesdopetam, covering various salt forms of the drug candidate. This patent enhances the intellectual property portfolio of mesdopetam, supporting its market exclusivity and commercialization efforts, which could significantly impact the company’s operations and industry positioning by extending market exclusivity into the mid-2040s across major markets.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish company focused on discovering and developing transformative treatments for Parkinson’s disease. Originating from Nobel Laureate Prof Arvid Carlsson’s research group, the company leverages its proprietary systems biology-based research platform, Integrative Screening Process (ISP), to generate its pipeline. Their key drug candidates include mesdopetam for levodopa-induced dyskinesias, pirepemat for reducing fall frequency, and IRL757 for treating apathy in neurodegenerative disorders.
Average Trading Volume: 200,811
Technical Sentiment Signal: Sell
Current Market Cap: SEK184.7M
See more data about IRLAB.A stock on TipRanks’ Stock Analysis page.